Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) traded down 6.7% on Tuesday . The company traded as low as $8.85 and last traded at $8.83. 890,042 shares were traded during mid-day trading, a decline of 73% from the average session volume of 3,316,285 shares. The stock had previously closed at $9.46.
Analyst Ratings Changes
A number of research firms recently commented on NTLA. Barclays decreased their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Truist Financial lowered their price target on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. JPMorgan Chase & Co. reissued a "neutral" rating and set a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Oppenheimer lowered their target price on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a research note on Monday, January 13th. Finally, Morgan Stanley lowered Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $37.56.
Read Our Latest Stock Report on Intellia Therapeutics
Intellia Therapeutics Price Performance
The stock has a market capitalization of $962.71 million, a price-to-earnings ratio of -1.71 and a beta of 1.97. The firm's fifty day moving average is $10.57 and its 200-day moving average is $14.98.
Insider Activity
In related news, CEO John M. Leonard sold 26,807 shares of the company's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Intellia Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the business. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $43,177,000. Voloridge Investment Management LLC grew its position in shares of Intellia Therapeutics by 226.8% during the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company's stock worth $17,805,000 after acquiring an additional 1,059,751 shares during the last quarter. Contrarius Group Holdings Ltd acquired a new stake in shares of Intellia Therapeutics in the 4th quarter worth about $11,798,000. Two Sigma Advisers LP lifted its position in Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock valued at $23,300,000 after purchasing an additional 970,700 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in Intellia Therapeutics by 88.1% during the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock valued at $21,498,000 after purchasing an additional 863,363 shares during the period. Institutional investors and hedge funds own 88.77% of the company's stock.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
